Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 25, 2025, details the results of Alzamend Neuro, Inc.'s Annual Meeting of Stockholders held on that date. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Capital Market under the symbol "ALZN". As of the record date (March 13, 2025), the Company had 6,597,508 shares of Common Stock, 2,100 shares of Series B Preferred Stock, and 97.7511 shares of Series C Convertible Preferred Stock outstanding.
Key Financial Metrics
This filing is a corporate governance report regarding stockholder votes and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting. The results were as follows:
- Proposal One (Election of Directors): All eight nominees were elected. Vote counts varied by nominee, with "For" votes ranging from approximately 1.85 million to 1.96 million. Notably, nominee Jeffrey Oram received 726,361 abstentions, significantly higher than other nominees.
- Proposal Two (Ratification of Auditors): Stockholders approved the ratification of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2025, with 4,255,027 votes "For" and 54,999 "Against".
- Proposal Three (Series C Conversion): Stockholders approved the conversion of Series C Preferred Stock into Common Stock and warrants. This action complies with Nasdaq Listing Rule 5635 regarding a Securities Purchase & Exchange Agreement dated February 28, 2025, with a total purchase price of up to $5,000,000.00 less a 5% discount. The proposal received 757,391 "For" votes and 142,345 "Against" votes.
- Proposal Four (Reverse Stock Split): Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of the Common Stock. The ratio is set between one-for-two and one-for-ten, to be determined by the Board of Directors at any time prior to April 24, 2026. The proposal received 3,252,166 "For" votes and 1,077,493 "Against" votes.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the reverse stock split authorization. The approval of the reverse stock split indicates a strategic move to adjust the share structure, potentially to maintain compliance with Nasdaq listing requirements regarding minimum bid price, though the specific ratio remains at the Board's discretion.
Key Facts for Investor Verification
- Reverse Stock Split Ratio: Verify the specific ratio (between 1:2 and 1:10) the Board of Directors selects and the implementation date prior to April 24, 2026.
- Series C Conversion Details: Confirm the exact number of Common Stock shares and warrants issued upon the conversion of the 97.7511 shares of Series C Preferred Stock.
- Director Support Levels: Review the high number of abstentions for director nominee Jeffrey Oram (726,361) compared to other nominees to assess potential governance concerns.
- Capital Structure Impact: Monitor the impact of the reverse stock split on the total share count and the conversion of Series C stock on the fully diluted share count.